Shares of MediGene AG (ETR:MDG1) were up 1.3% during mid-day trading on Wednesday . The company traded as high as €5.71 ($6.63) and last traded at €5.61 ($6.52), approximately 43,905 shares were traded during trading. A decline of 86% from the average daily volume of 306,207 shares. The stock had previously closed at €5.54 ($6.44).
Separately, Baader Bank set a €11.00 ($12.79) price target on MediGene and gave the company a “neutral” rating in a report on Wednesday, November 13th.
The company has a 50-day simple moving average of €5.72 and a 200-day simple moving average of €6.61. The stock has a market cap of $138.29 million and a PE ratio of -5.77. The company has a debt-to-equity ratio of 7.43, a current ratio of 5.10 and a quick ratio of 5.10.
About MediGene (ETR:MDG1)
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Featured Article: Trading Strategy
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.